Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients

Disease Markers

Volumn 26, Issue 3, 2009, Pages 141-148

  Varga, Éva ^a   Seres, Ildikó ^a   Harangi, Mariann ^a   Sztanek, Ferenc ^a   Asztalos, László ^a   Lcsey, Lajos ^b   Borbás, Béla ^b   Szegedi, János ^c   Kárpáti, István ^a   Paragh, Gyórgy ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Kenezy Korhaz Rendelointezet   (Hungary)

^c BBraun Dialysis Center   (Hungary)

Author keywords

Cystatin C; Homocysteine; Oxidative stress; Paraoxonase; Renal failure

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; AZATHIOPRINE; CYCLOSPORIN; CYSTATIN C; HOMOCYSTEINE; METHYLPREDNISOLONE; OXIDIZED LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HEMODIALYSIS; HUMAN; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPECTROMETRY;

EID: 68649087157     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2009-0624     Document Type: Article

References (31)

1. G.J. Kelso, W.D. Stuart, R.J. Richter, C.E. Furlong, T.C. Jordan-Starck and J.A. Harmony, Apolipoprotein J is associated with paraoxonase in human plasma, Biochemistry 33 (1994), 832-839.
2. H. Jakubowski, Calcium-dependent human serum homocys-teine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation, J Biol Chem 275 (2000), 3957-3962.
3. M. Lacinski, W. Skorupski, A. Cieslinski, J. Sokolows-ka, W.H. Trzeciak and H. Jakubowski, Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans, Cell Mol Biol (Noisy -le-grand) 50 (2004), 885-893.
4. H. Jakubowski, W.T. Ambrosius and J.H. Pratt, Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis, FEBS Lett 491(2001), 35-39.
5. G. Paragh, L. Asztalos, I. Seres, Z. Balogh, L. Locsey, I. Karpati, J. Matyus, E. Katona, M. Harangi and G. Kakuk, Serum paraoxonase activity changes in uremic and kidney-transplanted patients, Nephron 83 (1999), 126-131.
6. D.J. Newman, Cystatin C, Ann Clin Biochem 39 (2002), 89-104.
7. R. Hojs, S. Bevc, R. Ekart, M. Gorenjak and L. Puklavec, Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease, Ren Fail 30 (2008), 181-186.
8. M. Madero, M.J. Sarnak and L.A. Stevens, Serum cystatin C as a marker of glomerular filtration rate, Curr Opin Nephrol Hypertens 15 (2006), 610-616.
9. M. Abrahamson, M. Alvarez-Fernandez and C.M. Nathanson, Cystatins, Biochem Soc Symp (2003), 179-199.
10. E. Bengtsson, F. To, K. Hakansson, A. Grubb, L. Branen, J. Nilsson and S. Jovinge, Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice, Arterioscler, Thromb Vasc Biol 25 (2005), 2151-2156.
11. R. Clarke, S.Lewington and M. Landray, Homocysteine, renal function, and risk of cardiovascular disease, Kidney Int Suppl (2003), S131-S133.
12. A.B. Lawrence de Koning, G.H. Werstuck, J. Zhou and R.C. Austin, Hyperhomocysteinemia and its role in the development of atherosclerosis, Clin Biochem 36 (2003), 431-441.
13. H. Jakubowski, The molecular basis of homocysteine thiolactone-mediated vascular disease, Clin Chem Lab Med 45 (2007), 1704-1716.
14. H. Jakubowski, Pathophysiological consequences of homo-cysteine excess, J Nutr 136 (2006), 1741S-1749S.
15. C. Lewerin, S. Ljungman and H. Nilsson-Ehle, Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methyl-malonic acid in the elderly, J Intern Med 261 (2007), 65-73.
16. L. Locsey, J. Szegedi, A. Dan, S. Gorogh and E. Toths, Ho-mocysteine and cystatin C level changes in haemodialysed patients and connection with cerebro- and cardiovascular complications, Acta Physiol Hung 88 (2001), 293-299.
17. A.G. Bostom, R.Y. Gohh, A.J. Beaulieu, H. Han, P.F. Jacques, J. Selhub, L. Dworkin and I.H. Rosenberg, Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients, Transplantation 68 (1999), 257-261.
18. M.Kerkeni, F. Addad, M.Chauffert, L.Chuniaud, A. Miled, F. Trivin and K. Maaroufi. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease, Clin Biochem 39 (2006), 821-825.
19. H.W. Eckerson, C.M. Wyte and B.N.La Du, The human serum paraoxonase/arylesterase polymorphism, Am J Hum Genet 35 (1983), 1126-1138.
20. B.N. La Du, S. Adkins, C.L. Kuo and D. Lipsig, Studies on human serum paraoxonase/arylesterase, Chemico-Biological Interactions 87 (1993), 25-34.
21. Y. Hirata, K. Okawa, M. Ikeda, M. Seike, M. Matsumoto and H. Kodama, Low density lipoprotein oxidized in xanthoma tissue induces the formation and infiltration of foam cells, J Dermatol Sci 30 (2002), 248-255.
22. J. Frostegard, B. Kjellman, M. Gidlund, B. Andersson, S. Jin-dal and R. Kiessling, Induction of heat shock protein in mono-cytic cells by oxidized low density lipoprotein, Atherosclerosis 121 (1996), 93-103.
23. A. Bokenkamp, S. Herget-Rosenthal and R. Bokenkamp, Cys-tatin C, kidney function and cardiovascular disease, Pediatr Nephrol 21 (2006), 1223-1230.
24. F. Marumo, K. Kamata and M. Okubo, Deranged concentrations of water-soluble vitamins in the blood of undialyzed and dialyzed patients with chronic renal failure, Int J Artif Organs 9 (1986), 17-24.
25. N. Janel, K. Robert, K. Demuth, C. Gouedard, R. Barouki and J.F. Chasse, Inverse relationshipbetweenphenylacetate hydrolase activity of the serum PON1 protein and homocysteinemia in humans, Thromb Haemost 93 (2005), 182-183.
26. M.M. Murphy, J. Marsillach, J. Camps, J. Fernandez-Ballart, B. Mackness, M. Mackness, N. Ferre and J. Joven, Influence of PON1 polymorphisms on the association between serum paraoxonase 1 and homocysteinemia in a general population, Clin Chem 52 (2006), 781-782.
27. G. Ferretti, T. Bacchetti, E. Marotti and G. Curatola, Effect of homocysteinylation on human high-density lipoproteins: A correlation with paraoxonase activity, Metabolism 52 (2003), 146-151.
28. E. Nakano, F.A. Taiwo, D. Nugent, H.R. Griffiths, S. Aldred, M. Paisi, M. Kwok, P. Bhatt, M.H. Hill, S. Moat and H.J. Powers, Downstream effects on human low densitylipoprotein of homocysteine exported from endothelial cells in an in vitro system, J Lipid Res 46 (2005), 484-493.
29. J. Beltowski, Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig Med Dosw (Online) 59 (2005), 392-404.
30. A. Undas, J. Perla, M. Lacinski, W. Trzeciak, R. Kazmierski and H. Jakubowski, Autoantibodies against N-homocysteiny-lated proteins in humans: implications for atherosclerosis, Stroke 35 (2004), 1299-1304.
31. S.S. Prichard, Impact of dyslipidemia in end-stage renal disease, J Am Soc Nephrol 14 (2003), S315-S320.